{ "meta": { "data_length": 1, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A163", "status": "success", "status_code": 200, "timestamp_elapsed": 0.004098, "timestamp_received": "2026-09-25T00:14:06.657254+00:00Z", "timestamp_returned": "2026-09-25T00:14:06.661352+00:00Z", "trace_id": "1b87eac8-eed0-4e49-998e-ca78903f8938" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:gleevec:5:0", "type": "Statement", "description": "The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2006-10-19:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2006-10-19", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:gleevec", "type": "Document", "documentType": "Regulatory approval", "name": "Gleevec (imatinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Pharmaceuticals Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Gleevec", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "imatinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 21588, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-03-01", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:163", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:ASM", "conceptType": "Disease", "name": "Aggressive Systemic Mastocytosis", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": false, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:ASM", "code": "ASM", "name": "Aggressive Systemic Mastocytosis", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASM" ] } }, "objectTherapeutic": { "id": "tx:ncit:C62035", "conceptType": "Therapy", "name": "Imatinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:282388", "code": "282388", "name": "imatinib", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=282388" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4185917", "code": "4185917", "name": "Imatinib", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4185917" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:414460008", "code": "414460008", "name": "Imatinib", "system": "SNOMED", "systemVersion": "2026-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=414460008&edition=MAIN/2026-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1304107", "code": "1304107", "name": "imatinib", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1304107" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Bcr-Abl inhibition", "c-Kit inhibition", "PDGF-R inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C62035", "code": "C62035", "name": "Imatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:122", "present": false, "subject": { "id": "bmkr:122", "type": "CategoricalVariant", "name": "KIT p.D816V", "constraints": [ { "type": "DefiningAlleleConstraint", "allele": { "id": "ga4gh:VA.nhiDwIq1klrGm3wtWO4a4BiS0jdW79Wd", "type": "Allele", "name": "NP_000213.1:p.Asp816Val", "aliases": [ "NP_000213.1:p.D816V", "KIT p.D816V" ], "description": "VRS variation of NP_000213.1:p.Asp816Val", "digest": "nhiDwIq1klrGm3wtWO4a4BiS0jdW79Wd", "expressions": [ { "syntax": "hgvs.p", "value": "NP_000213.1:p.Asp816Val", "extensions": [ { "name": "hgvs.p_short", "value": "p.D816V" } ] } ], "location": { "id": "ga4gh:SL.FDPpCHrDqH_pR10oxpHZ17tyGhZXVnsj", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Amino acid position 816 of the Refseq protein NP_000213.1, which is the protein product of the MANE Select coding transcript for KIT (refseq:NM_000222.3).", "digest": "FDPpCHrDqH_pR10oxpHZ17tyGhZXVnsj", "sequenceReference": { "id": "ga4gh:SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB", "type": "SequenceReference", "name": "NP_000213.1", "aliases": [ "ensembl:ENSP00000288135.5", "ga4gh:SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB", "refseq:NP_000213.1" ], "description": "The protein product of the MANE Select coding transcript for KIT (refseq:NM_000222.3), corresponding to the Refseq protein accession NP_000213.1.", "moleculeType": "protein", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB", "residueAlphabet": "aa" }, "start": 815, "end": 816, "sequence": "D" }, "state": { "type": "LiteralSequenceExpression", "sequence": "V" } }, "relations": [] }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:6342", "conceptType": "Gene", "name": "KIT", "primaryCoding": { "id": "coding:hgnc:6342", "code": "HGNC:6342", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6342" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000157404", "code": "ENSG00000157404", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000157404" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:3815", "code": "3815", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/3815" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_000222.3", "code": "NM_000222.3", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_000222.3" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "4" }, { "name": "start_position", "value": 55599321 }, { "name": "end_position", "value": 55599321 }, { "name": "reference_allele", "value": "A" }, { "name": "alternate_allele", "value": "T" }, { "name": "cdna_change", "value": "c.2447A>T" }, { "name": "protein_change", "value": "p.D816V" }, { "name": "variant_annotation", "value": "Missense" }, { "name": "exon", "value": 17 }, { "name": "rsid", "value": "rs121913507" }, { "name": "hgvsg", "value": "4:g.55599321A>T" }, { "name": "hgvsc", "value": "ENST00000288135.5:c.2447A>T" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:gleevec:5", "type": "Indication", "description": "Gleevec is a kinase inhibitor indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2006-10-19:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2006-10-19", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:gleevec", "type": "Document", "documentType": "Regulatory approval", "name": "Gleevec (imatinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Pharmaceuticals Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Gleevec", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "imatinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 21588, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-03-01", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }